DoW Multiple Sclerosis Clinical Trial Award
Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSR
| Agency | Dept. of the Army -- USAMRAA |
|---|---|
| Status | Posted |
| Opportunity number | HT942526MSRPCTA |
| Posted date | 05/05/2026 |
| Application deadline | Aug 13, 2026 12:00:00 AM EDT |
| Award ceiling | none |
| Award floor | none |
| Estimated total funding | 4,000,000 |
| Expected number of awards | 3 |
| Assistance Listing (CFDA) | 12.420 |
| Description | Summary: The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Distinctive Features: The FY26 CTA offers two funding levels. The following are generalized descriptions of the scope of research appropriate for each funding level: • Funding Level 1 (CTA-FL1) supports small-scale, proof-of-principle clinical trials (e.g., pilot, first-in-human, phase 0) to |
| Agency contact | help@eBRAP.org |
| Official listing | https://www.grants.gov/search-results-detail/362227 |